Profile data is unavailable for this security.
About the company
Palisade Bio, Inc. is a biopharmaceutical company focused on developing novel therapeutics for serious chronic gastrointestinal diseases. It is engaged in advancing a PALI-2108 for the treatment of IBD, including UC and CD and are researching PALI-1908. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract. UC primarily affects the colon and the rectum. CD can affect any part of the gastrointestinal tract, from the mouth to the anus. PALI-2108 is a prodrug PDE4 inhibitor that operates through a mechanism within colon tissues, targeting the key enzyme phosphodiesterase-4 (PDE4). This enzyme is pivotal in cAMP hydrolysis, and by inhibiting PDE4, intracellular cAMP levels are elevated. This elevation leads to the downregulation of inflammatory cytokines and a reduction in the expression of cell adhesion molecules. By modulating these processes, PALI-2108 prevents the local infiltration and activation of inflammatory cells in the colon tissues.
- Revenue in USD (TTM)0.00
- Net income in USD-13.49m
- Incorporated2001
- Employees9.00
- LocationPalisade Bio Inc7750 El Camino Real, Suite 5200CARLSBAD 92009United StatesUSA
- Phone+1 (858) 704-4900
- Fax+1 (302) 697-4597
- Websitehttps://palisadebio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Neximmune Inc | 0.00 | -25.86m | 4.20m | 6.00 | -- | 1.53 | -- | -- | -24.16 | -24.16 | 0.00 | 2.16 | 0.00 | -- | -- | 0.00 | -130.41 | -115.07 | -183.16 | -165.07 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 48.25 | -- | -44.65 | -- |
| Processa Pharmaceuticals Inc | 0.00 | -9.83m | 4.23m | 13.00 | -- | 0.4758 | -- | -- | -6.29 | -6.29 | 0.00 | 3.11 | 0.00 | -- | -- | 0.00 | -87.82 | -84.35 | -102.32 | -90.03 | -- | -- | -- | -- | -- | -- | 0.0012 | -- | -- | -- | 59.45 | -- | -34.05 | -- |
| MyMD Pharmaceuticals Inc | 0.00 | -7.07m | 4.29m | 9.00 | -- | 0.1897 | -- | -- | -5.53 | -5.53 | 0.00 | 10.28 | 0.00 | -- | -- | 0.00 | -25.59 | -76.20 | -31.13 | -84.38 | -- | 7.64 | -- | -4,290.96 | -- | -- | 0.00 | -- | -- | -- | 49.15 | -- | -- | -- |
| Petros Pharmaceuticals Inc | 4.69m | -20.46m | 4.30m | 21.00 | -- | 0.4319 | -- | 0.9161 | -7.37 | -7.37 | 1.68 | 1.55 | 0.1542 | 0.7858 | 2.15 | 223,487.10 | -29.37 | -32.43 | -41.80 | -68.05 | 69.91 | 62.04 | -190.50 | -201.70 | 1.46 | -- | 0.4284 | -- | -2.83 | -16.15 | 31.06 | -- | -- | -- |
| Theriva Biologics Inc | 0.00 | -19.04m | 4.32m | 21.00 | -- | 0.1366 | -- | -- | -1.15 | -1.15 | 0.00 | 1.99 | 0.00 | -- | -- | 0.00 | -32.65 | -36.95 | -37.33 | -40.16 | -- | -- | -- | -- | -- | -- | 0.0064 | -- | -- | -- | 8.37 | -- | 95.91 | -- |
| Ensysce Biosciences Inc | 1.75m | -11.55m | 4.36m | 7.00 | -- | 1.12 | -- | 2.50 | -3.74 | -3.74 | 0.5109 | 0.5115 | 0.3886 | -- | 9.06 | 249,514.30 | -257.00 | -17.68 | -574.02 | -19.42 | -- | -- | -661.34 | -715.78 | -- | -6.25 | 0.0671 | -- | -11.61 | -- | 57.64 | -- | -- | -- |
| Cingulate Inc | 0.00 | -22.50m | 4.37m | 13.00 | -- | 1.09 | -- | -- | -22.66 | -22.66 | 0.00 | 0.6419 | 0.00 | -- | -- | 0.00 | -355.56 | -- | -1,198.96 | -- | -- | -- | -- | -- | -- | -33.88 | 0.0054 | -- | -- | -- | -33.14 | -- | -- | -- |
| Artelo Biosciences Inc | 0.00 | -9.60m | 4.42m | 5.00 | -- | 0.4637 | -- | -- | -3.13 | -3.13 | 0.00 | 2.95 | 0.00 | -- | -- | 0.00 | -66.62 | -- | -70.40 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 7.87 | -- | -- | -- |
| Palisade Bio Inc | 0.00 | -13.49m | 4.52m | 9.00 | -- | 0.4078 | -- | -- | -24.67 | -24.67 | 0.00 | 11.82 | 0.00 | -- | -- | 0.00 | -96.63 | -132.36 | -111.78 | -165.45 | -- | -- | -- | -27,892.32 | -- | -874.31 | 0.00 | -- | -- | -0.7814 | 13.74 | -- | 18.53 | -- |
| Geovax Labs Inc | 0.00 | -27.78m | 4.60m | 17.00 | -- | 77.40 | -- | -- | -14.42 | -14.42 | 0.00 | 0.0235 | 0.00 | -- | -- | 0.00 | -180.60 | -108.34 | -242.41 | -147.24 | -- | -- | -- | -1,842.93 | -- | -- | 0.00 | -- | -100.00 | -- | -85.20 | -- | -- | -- |
| Onconetix Inc | 758.90k | -45.68m | 4.61m | 12.00 | -- | -- | -- | 6.07 | -2.41 | -2.41 | 0.0407 | 1.91 | 0.0156 | -- | 4.70 | 63,241.67 | -93.67 | -- | -137.89 | -- | -123.62 | -- | -6,019.45 | -- | 0.2752 | -17.12 | 0.2352 | -- | -- | -- | -176.78 | -- | -- | -- |
| China Pharma Holdings Inc | 6.42m | -3.56m | 4.70m | 231.00 | -- | 0.5287 | -- | 0.7314 | -0.8352 | -0.8352 | 1.03 | 0.5596 | 0.3828 | 1.93 | 14.14 | 27,795.89 | -21.22 | -29.66 | -44.77 | -55.25 | -11.67 | 6.47 | -55.42 | -73.09 | 0.2523 | -11.34 | 0.261 | -- | -13.48 | -10.68 | 22.50 | -- | -25.78 | -- |
| Pineapple Inc | 157.59k | 376.69k | 4.75m | -- | 0.5834 | -- | 12.47 | 30.15 | 0.1114 | 0.1114 | 0.0028 | -0.0318 | 0.0388 | -- | -- | -- | 9.28 | -- | 53.43 | -- | -412.55 | -- | 239.03 | -- | 0.00 | -- | -- | -- | -- | -- | -611.10 | -- | -- | -- |
| NS Wind Down Co Inc | 162.47m | -166.43m | 4.81m | 703.00 | -- | -- | -- | 0.0296 | -3.53 | -3.53 | 3.44 | -1.05 | 0.4936 | 2.07 | 4.30 | 231,113.80 | -50.56 | -30.01 | -62.82 | -34.66 | 35.72 | 57.14 | -102.44 | -80.87 | 2.02 | -70.17 | 1.29 | -- | -12.28 | 2.06 | -38.43 | -- | 40.03 | -- |
| Lipella Pharmaceuticals Inc | 477.45k | -4.74m | 4.88m | 5.00 | -- | 1.76 | -- | 10.23 | -0.7633 | -0.7633 | 0.0747 | 0.3638 | 0.1232 | -- | 6.25 | 95,490.00 | -122.37 | -- | -146.33 | -- | -- | -- | -993.39 | -- | -- | -- | 0.00 | -- | 144.15 | -- | -77.81 | -- | -- | -- |
Data as of May 31 2024. Currency figures normalised to Palisade Bio Inc's reporting currency: US Dollar USD
7.28%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Armistice Capital LLCas of 31 Mar 2024 | 48.00k | 5.64% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 4.54k | 0.53% |
| Geode Capital Management LLCas of 31 Mar 2024 | 2.30k | 0.27% |
| HRT Financial LLCas of 31 Mar 2024 | 2.16k | 0.25% |
| Two Sigma Securities LLCas of 31 Mar 2024 | 1.88k | 0.22% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 1.50k | 0.18% |
| Millennium Management LLCas of 31 Mar 2024 | 1.21k | 0.14% |
| UBS Securities LLCas of 31 Mar 2024 | 148.00 | 0.02% |
| Morgan Stanley Smith Barney LLC (Investment Management)as of 31 Mar 2024 | 141.00 | 0.02% |
| Desjardins Securities, Inc.as of 31 Mar 2024 | 100.00 | 0.01% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
